Discovering New Ways to Approach the Treatment of Rare Brain Tumors

Until a few years ago, there were only a handful of known survivors of atypical teratoid rhabdoid tumor (AT/RT), a rare cancer that affects the brain and central nervous system. When researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center studied how these few survivors were treated, they found three had been given an unusual chemotherapy regimen. They decided to try that therapy with several new and relapsed patients.

discoveries into new brain tumor treatments

Brain tumor experts Keith Ligon, MD, PhD, and Mark Kieran, MD, PhD

“We had two kids with newly diagnosed AT/RT and two that had relapsed, and three of them did very well,” says Mark Kieran, MD, PhD, director of Medical Neuro-Oncology at Dana-Farber/Boston Children’s. “Basically, we doubled the number of known survivors of this disease.”

After this initial success, physicians at Dana-Farber/Boston Children’s launched a national trial on the chemotherapy regimen. Over half the children in that trial became long-term survivors.

According to Kieran, the therapy may also see applications in treating adult breast, prostate, lung and colon cancers.

Learn more about this treatment in the video below and at discovercarebelieve.org:

Make An Appointment

For adults: 877-960-1562

Quick access: Appointments as soon as the next day for new adult patients

For children: 888-733-4662

All content in these blogs is provided by independent writers and does not represent the opinions or advice of Dana-Farber Cancer Institute or its partners.

Latest Tweets

Dana-Farber @danafarber
Dr. Matthew Davids explores combining ibrutinib with FCR (iFCR) for younger patients with previously-untreated chro… https://t.co/wzVpo47tSa
Dana-Farber @danafarber
“We’re changing the way people are cared for, through #precisionmedicine, precision care, and a total team approach… https://t.co/RnZXsH2rW8
Dana-Farber @danafarber
Cell-weighing method could help doctors choose #cancer drugs: https://t.co/YesjtyxIvR via @MIT https://t.co/0F7wsZSuLJ

Republish our posts on your blog

Interested in sharing one of our stories on your blog? Feel free to republish this content! We just ask that you credit Dana-Farber, link to the original article, and refrain from making edits that change the original context. Questions? Email the editors at insight_blog@dfci.harvard.edu.